Pfizer applied for the reimbursement of its COVID-19 treatment 'Paxlovid' in Korea.

With the government planning to end the current free support system for COVID-19 treatments in the 1H next year, the company has begun the process of applying for reimbursement accordingly.

According to the industry on the 5th, Pfizer Korea recently submitted a drug decision application for its COVID-19 treatment ‘Paxlovid Tab’ to the Health Insurance Review and Assessment Service.

Paxlovid was first introduced to Korea through the Emergency Use Authorization system in December 2021. At the time, the need for oral treatment was raised due to the increased number of confirmed COVID